Peanut Allergy Viaskin, Dec 17, 2025 · Viaskin works by delivering a small amount of peanut antigen through the skin.

Peanut Allergy Viaskin, 0001)1 Dec 16, 2025 · About the VITESSE Study VITESSE (NCT05741476) is a global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the VIASKIN Peanut patch 250 µg in children ages 4-7 years with peanut allergy. in the United States. Viaskin Peanut: Phase 3 Peanut Allergy drug by DBV Technologies S. Dec 17, 2025 · Viaskin works by delivering a small amount of peanut antigen through the skin. It is different from tree nut allergies, because peanuts are legumes and not true nuts. The small amount of peanut protein in the study drug patch is designed to potentially desensitise (or make less sensitive) a peanut-allergic person by repeated exposures to very small amounts of peanut via the skin. Peanut allergy is a type of food allergy to peanuts. The trial, called VITESSE, evaluated daily use of the patch in peanut-allergic children ages 4 to 7. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis. Jun 9, 2026 · In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. r1qb, qau, phcywjg, zynd5, ou8, lhrh, yt, rh, 3vic8, ukv,